Eric Samorodnitsky
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
69
Citations
1,043
Est. group size
~12
Recurring co-author estimate
Active years
17
Publishing since 2010
Eric Samorodnitsky's research focuses on the genomics of cancer, particularly cholangiocarcinoma (bile duct cancer) and other tumors driven by alterations in FGFR (fibroblast growth factor receptor) genes. Work includes clinical trials of FGFR-targeted drugs, rapid-autopsy studies tracking how cancers evolve and spread, and development of software and liquid-biopsy tools to detect genomic alterations that affect tumor immune response and treatment outcomes. This work bridges laboratory genomic analysis with clinical trial data to guide precision oncology treatment decisions.
Publication output was low and steady through 2017-2022, then spiked sharply in 2023 before settling into a moderate, continuing pace through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 377 FGFR protein phosphorylation as a biomarker for FGFR-targeted therapy in cholangiocarcinoma
Journal of Clinical and Translational Science · 2026
- 26Rapid Autopsy Unravels Clonal Drivers of Metastatic Progression in FGFR2-Driven Cholangiocarcinoma
The Oncologist · 2026
- A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B‐Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation
European Journal Of Haematology · 2025
- Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers
npj Precision Oncology · 2025
- A phase IIa clinical trial of first-line cyclical therapy alternating gemcitabine, cisplatin, and durvalumab with pemigatinib for advanced biliary tract cancers with <i>FGFR2</i> -alterations.
Journal of Clinical Oncology · 2025
- 532 Evaluating fibroblast growth factor receptor (FGFR) pathway mRNA expression and protein activation in cholangiocarcinoma tumors
Journal of Clinical and Translational Science · 2025
- 1229 14q deletion in renal clear cell carcinoma is associated with increased anti-tumor immunity and improved response to PD-1 checkpoint blockade potentially driven by NF-κB signaling
Regular and Young Investigator Award Abstracts · 2025
- Rapid Autopsy Multi-Omic Analysis Identifies Divergent Evolutionary Trajectories and DNA Damage Resistance Mechanisms in FGFR2-Driven Cholangiocarcinoma
medRxiv · 2025
- Analytic validation of an <i>FGFR</i> -focused cell-free DNA liquid biopsy assay (FGFR-Dx)
medRxiv · 2024
- Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib
Haematologica · 2024
- FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer
npj Precision Oncology · 2024
- A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with <i>FGFR2</i> gene fusions or other <i>FGFR</i> genetic alterations.
Journal of Clinical Oncology · 2024
- RIGATonI: An R software for Rapid Identification of Genomic Alterations in Tumors affecting lymphocyte Infiltration
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations
JCO Precision Oncology · 2023
- Abstract 3395: Clinical impact of FGFR inhibitors on FGFR2 positive pancreatic cancer
Cancer Research · 2023
- Cancer Research×6
- Molecular Cancer Therapeutics×2
- npj Precision Oncology×2
- JCO Precision Oncology×2
- Molecular Case Studies×2
- Julie W. Reeser
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Amy Smith
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Michele R. Wing
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Sameek Roychowdhury
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Thuy Dao
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile